bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis by McCurrach,  M. E. et al.
Proc. Natl. Acad. Sci. USA
Vol. 94, pp. 12094–12099, October 1997
Medical Sciences
Selective induction of p53 and chemosensitivity in RB-deficient
cells by E1A mutants unable to bind the RB-related proteins
ANDREW V. SAMUELSON AND SCOTT W. LOWE*
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724
Edited by Arnold J. Levine, Princeton University, Princeton, NJ, and approved August 29, 1997 (received for review July 2, 1997)
ABSTRACT The adenovirus E1A oncoprotein renders
primary cells sensitive to the induction of apoptosis by diverse
stimuli, including many anticancer agents. E1A-expressing
cells accumulate p53 protein, and p53 potentiates drug-
induced apoptosis. To determine how E1A promotes chemo-
sensitivity, a series of E1A mutants were introduced into
primary human and mouse fibroblasts using high-titer re-
combinant retroviruses, allowing analysis of E1A in geneti-
cally normal cells outside the context of adenovirus infection.
Mutations that disrupted apoptosis and chemosensitivity
separated into two complementation groups, which correlated
precisely with the ability of E1A to associate with either the
p300yCBP or retinoblastoma protein families. Furthermore,
E1A mutants incapable of binding RB, p107, and p130 con-
ferred chemosensitivity to fibroblasts derived from RB-
deficient mice, but not fibroblasts from mice lacking p107 or
p130. Hence, inactivation of RB, but not p107 or p130, is
required for chemosensitivity induced by E1A. Finally, the
same E1A functions that promote drug-induced apoptosis also
induce p53. Together, these data demonstrate that p53 accu-
mulation and chemosensitivity are linked to E1A’s oncogenic
potential, and identify a strategy to selectively induce apopto-
sis in RB-deficient tumor cells.
Despite the widespread use of cytotoxic agents to treat cancer,
the molecular mechanisms underlying drug sensitivity and
resistance remain poorly understood. Most anticancer agents
induce apoptosis, suggesting that tumor-cell chemosensitivity
is influenced by the efficiency with which anticancer agents
activate apoptotic programs (1, 2). This hypothesis implies that
responsive tumors must be more susceptible to apoptosis than
normal tissue, and that resistant tumors are unable to effi-
ciently engage apoptotic programs. Tumorigenic mutations
can have different effects on apoptosis. For example, activa-
tion of the c-myc oncogene enhances apoptosis (3) whereas
inactivation of the p53 tumor suppressor gene suppresses cell
death (reviewed in ref. 4). These diverse effects suggest that
tumor-cell chemosensitivity is determined, in part, by the
combined effects of oncogenic mutations on apoptosis (1, 5).
Given the varied impact of oncogenic mutations on apo-
ptosis, it is difficult to study the molecular determinants of
chemosensitivity in the unknown genetic background of tumor
cells. However, cells expressing the adenovirus early region 1A
(E1A) oncogene provide a simple model for studying cellular
processes that modulate chemosensitivity. E1A promotes apo-
ptosis in nontumorigenic cells (6). As a consequence, E1A-
expressing cells become extremely sensitive to toxic agents and
readily undergo apoptosis following treatment with anticancer
agents (1, 7).
E1A can impinge on a variety of other cellular processes,
including transcription, differentiation, and tumor necrosis
factor cytolysis (reviewed in ref. 8). During adenovirus infec-
tion, E1A makes quiescent cells permissive for virus replica-
tion by promoting S phase entry (8). Consequently, E1A has
oncogenic potential: E1A facilitates the immortalization of
primary rodent cells and cooperates with viral (e.g., E1B) or
cellular (e.g., oncogenic ras) genes to transform primary cells
to a tumorigenic state (9). E1B prevents the apoptosis asso-
ciated with E1A (6), whereas E1A prevents a senescent-like
cell cycle arrest provoked by oncogenic Ras (10). Conse-
quently, these transforming interactions illustrate the compen-
satory mechanisms normal cells possess to suppress transfor-
mation (reviewed in ref. 11).
The E1A gene expresses several alternatively spliced tran-
scripts, including the 12S and 13S messages encoding 243
(243R) and 289 (289R) amino acid oncoproteins, respectively
(reviewed in ref. 12). The 289R protein contains three regions
that are conserved between different adenovirus serotypes,
designated conserved regions 1, 2, and 3 (CR1, CR2, CR3).
CR3 encodes a domain required for transcriptional activation
of other viral genes and is absent in the 243R protein, whereas
CR1 and CR2 are present in both E1A proteins and are
essential for many E1A activities, including oncogenic trans-
formation (13, 14).
E1A 243R associates with a series of cellular proteins,
including the retinoblastoma gene product (RB), the RB-
related proteins p107 and p130, the p300 and CREB binding
protein (CBP) transcriptional coactivators, cyclin A, and cer-
tain cyclin-dependent kinases (cdk) (refs. 13 and 14; reviewed
in refs. 15 and 16). Because most of these interactions also
require residues in CR1 and CR2, the ability of E1A to disrupt
the function of these proteins may be crucial for its transform-
ing activities. For example, E1A associates with RB (14, 17)
and mutations in either CR1 or CR2 that disrupt this inter-
action also abolish oncogenicity (13). By binding RB, E1A
disrupts RB-E2F heterodimers, thereby relieving repression
and promoting transactivation of S phase genes (reviewed in
refs. 15 and 16). Mutational inactivation of RB achieves a
similar effect; consequently, E1A mimics mutational events
that occur in familial retinoblastoma and many sporadic
tumors (reviewed in ref. 18).
In adenovirus-infected cells, E1A expression appears suffi-
cient for apoptosis (19–21). However, cells tolerate ectopic
E1A expression but become extremely prone to apoptosis (1,
7). E1A-expressing cells accumulate p53 protein, and both p53
and Bax—a pro-apoptotic member of the Bcl-2 family—
contribute to apoptosis in this setting (1, 7, 22–25). p53 and Bax
are inefficient at inducing apoptosis in normal cells lacking
E1A (7); indeed, p53 functions to promote cell-cycle arrest
(26). Furthermore, E1A-expressing cells possess a discrete
factor, absent in normal cells, that is capable of activating the
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apoptotic machinery in a cell-free system (27). Hence, E1A
enables cells to more efficiently engage the apoptotic machin-
ery.
In this study, we examined how E1A promotes p53 accu-
mulation and chemosensitivity. To this end, we stably ex-
pressed E1A or a series of E1A mutants in primary human and
mouse fibroblasts using high-titer recombinant retroviral vec-
tors. Using this approach, we genetically defined multiple E1A
activities that act in concert to promote p53 accumulation and
chemosensitivity and demonstrate that one of these functions
involves inactivation of the RB gene product.
MATERIALS AND METHODS
Cells and Cell Culture. Mouse embryonic fibroblasts
(MEFs) were isolated as described (10). Cells were maintained
in DMEM (GIBCO) supplemented with 10% fetal bovine
serum and 1% penicillin-Gystreptomycin sulfate (Sigma).
RB2/2 MEFs were obtained from T. Jacks (28), p1072/2 and
p1302/2 MEFs were from N. Dyson (29, 30). IMR90 cells
overexpressed the murine ecotropic receptor, allowing infec-
tion with ecotropic retroviruses (10). MEFs were used between
passages three and six, IMR90 cells between 20–30 population
doublings.
E1A Mutants, Retroviral Vectors, and Infections. The 12S
E1A cDNA and 12S E1A deletion or point mutants (31, 32)
were subcloned into pLPC (10) or pWZLHygro (unpublished
data; J. P. Morgenstern, M. J. Zoller, and J. S. Brugge, Ariad
Pharmaceuticals, Cambridge, MA). pLPC-12S coexpresses an
E1A 12S cDNA with puromycin phosphotransferase (puro)
and pWZL-12S coexpresses E1A with hygromycin phospho-
transferase (hygro). The E1A mutant constructs used in this
study were as follows: pLPC 12S.DN, pLPC 12S.DCR1, pLPC
12S.DCR2, pLPC 12S.pm47y124, pWZL 12S.DN, pWZL
12S.DCR1, and pWZL 12S.DCR2.
Ecotropic retroviruses were produced using the Phoenix
packaging line (provided by G. Nolan, Stanford University)
according to a previously described procedure (10). Cells were
placed into medium containing 2.5 mgyml puromycin (Sigma)
or 100 mgyml hygromycin B (Boehringer Mannheim) to elim-
inate uninfected cells. When two separate E1A mutants were
coexpressed, they were introduced sequentially, the first using
LPC and the second using WZLHygro, with drug selection for
2–3 days after each infection.
Cell Viability. Cells (1 3 105) were plated into 12-well plates
24 h before treatment. Twenty-four hours following treatment
with adriamycin, or 48 h after serum withdrawal, adherent and
nonadherent cells were pooled and analyzed for viability by
trypan blue exclusion. At least 200 cells were counted for each
point. Null mutant fibroblasts were compared with cells de-
rived from wild-type littermate controls.
Protein Expression. Proteins were extracted in Nonidet P-40
lysis buffer [150 mM NaCly1% Nonidet P-40y50 mM TriszHCl,
pH 7.5y1 mM phenylmethylsulfonyl f luoridey1 mM EDTAy2
mg/ml CLAP (chymostatin, leupeptin, antipain, and pepsta-
tin)] for 1 h on ice with frequent vortex mixing. Lysates were
normalized by Bradford method (Bio-Rad), and 20 mg (for
p53) or 10 mg (for E1A) of total protein was loaded in each
lane. After electrophoresis, proteins were transferred to Im-
mobilon-P membranes (Millipore) using standard ‘‘wet’’ trans-
fer procedures. E1A was detected using either the M58 or M73
(1:100 dilution) mAbs (33), the latter recognizes an epitope
retained in all E1A mutants studied (34). The CM1 and CM5
polyclonal antibodies were used (1:1,000) to detect human and
mouse p53, respectively (Novocastra, Newcastle, U.K.). Pro-
teins were visualized by ECL (Amersham), and equal sample
loading was confirmed by India Ink.
RESULTS
To determine how E1A promotes chemosensitivity, we began
a structure–function analysis to identify the regions of E1A
required for this effect. A series of recombinant retrovirus
vectors coexpressing various E1A mutants (Fig. 1A) with
either puro or hygro were constructed. Earlier studies demon-
strated that the 243-amino acid protein encoded by the E1A
12S cDNA was sufficient for apoptosis and chemosensitivity
(7, 22); hence, all mutants were derived from an E1A 12S
cDNA (31, 32). These mutants were chosen because they are
compromised in their ability to physically associate with either
the p300yCBP (DN and DCR1) or RByp107yp130 (pm47y124
and DCR2) family of cellular proteins (Fig. 1A) (31).
High-titer ecotropic retroviruses were generated using a
transient retrovirus packaging system (35). Virus supernatants
were used to infect either normal diploid IMR90 human lung
fibroblasts or primary MEFs, and pure populations of E1A-
expressing cells were isolated by brief selection in the presence
of puromycin or hygromycin B. All E1A mutant proteins were
efficiently expressed (Fig. 1B). Using this approach, we were
able to stably express E1A in primary cell populations in the
absence of additional adenoviral proteins—i.e., in a genetically
normal background.
Multiple E1A Regions Are Required for Apoptosis and
Chemosensitivity. Full-length E1A rendered both human and
mouse fibroblasts sensitive to the induction of apoptosis by a
variety of agents (Fig. 2; data not shown). As expected, mouse
cells expressing E1A lost viability in a dose-dependent manner
FIG. 1. Structure and expression of E1A mutants. (A) The E1A
243R contains two conserved regions (CR1 and CR2, white boxes). In
the E1A mutants, deletions are indicated by gaps, and point mutations
by an ‘‘x.’’ DN, DCR1, and DCR2 are deletions of amino acids 2–36,
68–85, and 120–140, respectively. pm47y124 mutant has a tyrosine to
histidine and cysteine to glycine changes at amino acids 47 and 124,
respectively. Cellular proteins able to interact with each E1A mutant
in coimmunoprecipitations are indicated (31). (B) E1A was intro-
duced into IMR90 cells using LPC-based retroviral vectors. After
selection in puromycin, E1A levels were determined by Western blot
analysis. E1A is highly phosphorylated and undergoes posttransla-
tional modification, which accounts for variable migration in SDS gels
(33). Note that the DN mutant was able to coimmunoprecipitate
similar levels of RB as wild-type E1A (data not shown). Infection
efficiencies were .50% before selection and .95% of the cells in the
selected cells expressed E1A as determined by immunofluorescence
(data not shown). Each E1A mutant localized to the nucleus (data not
shown).
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following adriamycin treatment or serum withdrawal (Fig. 2 B
and C). Under these conditions cell death is largely p53-
dependent, because p53-deficient MEFs expressing E1A re-
mained viable (data not shown; see also refs. 1 and 7). Human
cells also lost viability following adriamycin treatment (Fig.
2A), but not after serum withdrawal (data not shown). In both
cell types, the dying cells displayed features of apoptosis (1, 7).
Fibroblasts infected with an empty vector did not undergo
apoptosis after either treatment (Fig. 2).
All of the E1A mutants were defective in promoting che-
mosensitivity in both human and mouse fibroblasts (Fig. 2).
IMR90 cells expressing DN, pm24y147, or DCR2 were com-
pletely insensitive to adriamycin treatment (Fig. 2 A). Al-
though IMR90 cells expressing the DCR1 mutant lost viability
in a dose-dependent manner, cell death was substantially
reduced compared with full-length E1A (35% vs. 11% viable
at 0.5 mgyml, respectively) (Fig. 2A). Like IMR90 cells, MEFs
expressing DN or DCR1 remained completely or partially
insensitive to adriamycin treatment, respectively (Fig. 2B). By
contrast, MEFs expressing either the pm47y124 or DCR2
mutants displayed modest levels of cell death, but only at the
higher doses (Fig. 2B). MEFs expressing each E1A mutant
were also defective in apoptosis following serum withdrawal,
a treatment not known to produce cellular damage (Fig. 2C).
The behavior of each E1A mutant was independent of the
apoptotic stimulus, because similar results were obtained
following treatment of human and mouse cells with etoposide,
cisplatin, 5-f luorouracil, or g-radiation (data not shown).
Therefore, multiple regions of E1A are required for apoptosis
following treatment with diverse agents.
Functionally Distinct Regions of E1A Cooperate to Confer
Chemosensitivity. Each E1A mutant defective in apoptosis is
also impaired for binding either the p300yCBP or RB-related
proteins (see Fig. 1) (31), raising the possibility that these
processes are related. However, the observations are correla-
tive, and it is also possible that these mutations affect one or
more unknown E1A activities. To establish whether multiple
E1A functions contribute to apoptosis, combinations of E1A
mutants were expressed in a trans complementation assay. If
two E1A mutants were defective because they lacked the same
function(s), they would be unable to function in trans to confer
chemosensitivity. Conversely, if two mutants were defective
owing to loss of separate functions, then coexpressing these
mutants might restore chemosensitivity. Therefore, E1A mu-
tants were introduced sequentially into IMR90s and MEFs
using retroviruses coexpressing different selectable markers
(puro and hygro).
In both human and mouse fibroblasts, E1A mutants that
bound different classes of cellular proteins acted in trans to
restore chemosensitivity, whereas those that bound the same
class did not (Fig. 3). For example, although cells expressing
either the DN or DCR2 mutant alone were insensitive to
adriamycin-induced apoptosis, the levels of apoptosis in cells
coexpressing these mutants approached those observed in cells
expressing full-length E1A (Fig. 3 A and B). Similar results
were observed when cells were treated with other anticancer
agents or following serum withdrawal (data not shown).
Likewise, cells coexpressing the DCR1 and DCR2 mutants
were as sensitive to adriamycin-induced apoptosis as cells
expressing full-length E1A (Fig. 3 C and D). No increase in
chemosensitivity was observed when cells were infected se-
quentially with the same E1A mutant (e.g., DN or DCR1)
compared with cells infected only once (data not shown). This
finding indicates that the cooperativity between DN or DCR1
with DCR2 did not result from increased gene dosage, but
rather was due to synergy between separate E1A functions.
Thus, multiple E1A activities contribute to chemosensitivity.
In contrast, the DN and DCR1 mutants failed to restore
chemosensitivity when expressed in trans: cells coexpressing
DN and DCR1 behaved identically to cells expressing the
partially defective DCR1 mutant alone (Fig. 3 E and F). As
discussed above, both DN and DCR1 restored chemosensitivity
when coexpressed with DCR2, implying that the DN and DCR1
mutations did not produce global aberrations in E1A structure,
but rather, disrupted the same function(s). The fact that two
E1A mutants that fail to bind p300yCBP (see Fig. 1) (31) are
defective for apoptosis because they affect overlapping func-
tions suggests that binding of one or more of these proteins is
required for chemosensitivity.
Role of CR2 in Chemosensitivity. CR2 is required for the
physical association between E1A and the RB-related proteins
(14). In principle, CR2 could contribute to chemosensitivity by
inactivating one or more of these proteins or by affecting some
other cellular activity. If CR2 promotes chemosensitivity by
inactivating a single RB-related protein, then the DCR2 mu-
tant should behave like full-length E1A in cells lacking this
crucial target. Because all of the RB-related genes have been
FIG. 2. Multiple regions of E1A are required for chemosensitivity. Primary mouse (MEF) (A and C) or human (IMR90) (B) fibroblasts were
infected with an empty vector (vector, E), vectors expressing full-length E1A (F), or the following mutants: DN (m), DCR1 (h), DCR2 (), and
pm47ypm124 (). Infected populations were plated in multiwell dishes and treated with the indicated concentrations of adriamycin (A and B) or
serum (C). Cell viability was determined 24 h following adriamycin treatment or 48 h after serum withdrawal. Previous studies demonstrated that
cell death under these conditions results from apoptosis (1, 7), and this was confirmed by visualizing chromatin condensation using
49,6-diamidino-2-phenylindole (data not shown). Each value represents the mean 6 SD from at least three separate experiments.
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disrupted in mice and all are expressed in MEFs (28–30, 36),
this hypothesis could be tested definitively.
E1A and the DCR2 mutant were introduced into wild-type,
RB2/2, p1072/2, or p1302/2 MEFs, and the resulting popula-
tions were treated with apoptosis-inducing stimuli (Fig. 4).
Adriamycin treatment induced similar levels of apoptosis in
cells expressing full-length E1A, irrespective of their genotype.
Thus, as expected, loss of the RB-related proteins does not
impair apoptosis. Furthermore, MEFs infected with the empty
vector were insensitive to adriamycin treatment, demonstrat-
ing that loss of either RB, p107, or p130 was not sufficient to
produce chemosensitivity (data not shown).
Concordant with previous results, wild-type MEFs express-
ing DCR2 are relatively insensitive to adriamycin treatment
(Fig. 4 Upper Left). Likewise, p1072/2 and p1302/2 cells
expressing DCR2 remained insensitive to adriamycin treat-
ment. By contrast, RB2/2 cells expressing DCR2 (Fig. 4) or
pm47y124 (data not shown) were as sensitive to adriamycin-
induced apoptosis as cells expressing full-length E1A. This
synergy was specific for DCR2 and pm47y124, because the DN
mutant remained defective in all cell types (Fig. 4 Lower).
Thus, inactivation of RB—but not p107 or p130—is the critical
function of CR2 important for apoptosis. Furthermore, E1A
mutants unable to bind RB are defective in normal cells but
promote apoptosis in cells with mutant RB genes.
p53 Accumulation and Chemosensitivity Involve the Same
E1A Functions. Cells expressing E1A accumulate p53 protein
due, in part, to increased p53 stability (22). To determine
whether p53 accumulation and chemosensitivity involve the
same E1A functions, we examined the ability of each E1A
mutant to induce p53. Cells expressing full-length E1A dis-
played a 20- to 30-fold increase in steady-state p53 protein
levels (Fig. 5A). The DN and DCR2 mutants produced only a
slight increase in p53 levels in IMR90 cells, and no increase in
MEFs. However, coexpression of both mutants induced p53 to
levels observed in cells expressing full-length E1A (Fig. 5A).
Remarkably, DCR2 induced p53 when expressed in RB2/2
MEFs (30-fold increase), but not in p1072/2 or p1302/2 MEFs
(Fig. 5B). RB2/2 cells infected with the empty vector displayed
no increase in p53 levels (data not shown). Thus, the same E1A
functions that promote apoptosis and chemosensitivity also
induce p53.
DISCUSSION
Despite the widespread use of cytotoxic agents to treat cancer,
molecular factors that influence tumor-cell chemosensitivity
remain largely unknown. The E1A oncoprotein displays a
remarkable ability to enhance chemosensitivity, and acts to
promote drug-induced apoptosis (1, 7, 37). In this study, we
demonstrate that at least two independent E1A functions act
in concert to promote apoptosis and chemosensitivity, and that
one function involves inactivation of the retinoblastoma gene
product. Of note, the regions of E1A that promote apoptosis
are similar, if not identical, to those previously shown to
facilitate oncogenic transformation (13, 14). Consequently,
our results underscore the association between factors that
influence tumorigenesis and tumor-cell chemosensitivity.
In the context of adenovirus infection, the E1A regions
involved in binding the p300yCBP and RB-related proteins
have been associated with apoptosis. However, depending on
the setting, only the p300yCBP binding region, either the
p300yCBP or RB-related protein binding region, or both
regions were required (38–40); hence, the results are contra-
dictory. Moreover, in one study, p53 accumulation did not
correlate with apoptosis (39). Another study examined the
FIG. 3. Separate E1A functions cooperate to confer chemosensi-
tivity. IMR90 or MEF cell populations expressing E1A (F), DN (m),
DCR1 (h), DCR2 (), DN and DCR2 (E in A and B), DCR1 and DCR2
(E in C and D), or DN and DCR1 (E in E and F) were generated by
retroviral infection. Multiple E1A mutants were introduced sequen-
tially as described in Materials and Methods. Cell populations were
treated with adriamycin and viability was determined 24 h later by
trypan blue exclusion. Each value represents the mean 6 SD of the
data from at least three separate experiments.
FIG. 4. Inactivation of RB by CR2 is required for chemosensitivity.
Wild-type, RB2/2, p1072/2, and p1302/2 MEFs expressing either E1A
(F), DCR2 (E, Upper), or DN (E, Lower) were generated by retroviral
infection. E1A and E1A mutants were expressed at similar levels (data
not shown). Cell viability was determined 24 h after adriamycin
treatment. Each point represents the mean 6 SD from at least three
separate experiments.
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relationship between E1A and chemosensitivity in a tumori-
genic cell line. Here, the regions of E1A capable of conferring
chemosensitivity varied with the agent tested (41). However,
even full-length E1A did not substantially enhance apoptosis
in these cells, and no correlation between p53 accumulation
and chemosensitivity was observed. Furthermore, this study
did not support an absolute requirement for RB inactivation
for chemosensitivity. All previous studies have been correla-
tive: none provides direct evidence that the cellular proteins
targeted by E1A participate in apoptosis.
The studies described above examined E1A in immortal or
tumor-derived lines, often in the context of adenovirus infec-
tion. However, E1A is a transforming oncogene that itself
facilitates immortalization (9); hence, immortal or tumor-
derived cells may already have alterations in processes affected
by E1A. This may explain why the RB-binding domain of E1A
was dispensable for apoptosis in HeLa cells (38, 39)—these
tumor cells express papillomavirus E7, an oncoprotein that
inactivates RB. Likewise, adenovirus contains several genes
that affect apoptosis in addition to EIA (6, 42) and can induce
apoptosis in the absence of E1A (39). In this study, retrovirus-
mediated gene transfer was used to introduce E1A into whole
populations of primary cells, allowing E1A to be studied in the
absence of other adenoviral genes and unknown host-cell
mutations.
All E1A mutants tested showed marked reduction in apo-
ptotic potential in both primary human and mouse fibroblasts,
and the requirement for each E1A region was independent of
the apoptotic stimulus. These regions correlated precisely with
the ability of E1A to associate with the p300yCBP or RB-
related proteins. Coexpression of E1A mutants binding sepa-
rate classes of cellular proteins functioned in trans to confer
chemosensitivity, whereas coexpression of mutants binding the
same cellular proteins did not. Thus, this study genetically
defines at least two E1A functions that act in concert to
promote apoptosis and chemosensitivity.
As has been observed during adenovirus-induced apoptosis
(38–40), our results provide genetic evidence that E1A’s
interaction with the p300yCBP proteins is critical for chemo-
sensitivity. Here, we used a genetic complementation test to
demonstrate that two spatially separate E1A mutations, both
known to disrupt p300yCBP binding (DN and DCR1), affect
the same E1A function(s) involved in chemosensitivity.
Whereas DCR1 is unable to associate with p300yCBP in
immunoprecipitations, it retains some capacity to affect p300y
CBP functions in cells (32, 43). By contrast, the DN mutant is
completely defective in p300yCBP interaction using both
immunoprecipitations and functional assays. Perhaps this ex-
plains why the DN and DCR1 mutants displayed a complete
and partial defect in apoptosis, respectively (see Fig. 3). p300
and CBP are both transcriptional coactivators and histone
acetyltransferases (ref. 44; reviewed in ref. 45), and E1A
binding to p300 produces global changes in transcription
(reviewed in ref. 16). Recent studies suggest that p300 and CBP
physically associate with p53 and contribute to p53’s transcrip-
tional activity, raising the possibility that E1A binding to p300
modulates p53 function to promote apoptosis (46–48). Alter-
natively, the critical target may not be p300yCBP itself, but
another molecule displaced or altered by the E1A–p300yCBP
interaction.
In addition to the apparent p300yCBP binding activity, a
second E1A function is required for apoptosis and chemosen-
sitivity. Using primary fibroblasts derived from RB2/2,
p1072/2, or p1302/2 mice, we conclusively demonstrate that
this function involves inactivation of RB, but not p107 or p130.
Interestingly, inactivating mutations in the RB gene occur in
many human cancers; by contrast, mutations in p107 or p130
have not been observed (18). The fact that E1A promotes
chemosensitivity by inactivating a tumor suppressor under-
scores the utility of viral oncogenes to identify processes
relevant to human cancer. Furthermore, the critical role of RB
inactivation for apoptosis reiterates the fundamental relation-
ship between tumorigenesis and chemosensitivity.
How RB inactivation contributes to apoptosis and chemo-
sensitivity remains to be determined. RB-deficient mice display
elevated apoptosis in the embryonic lens, fetal liver, and the
developing nervous system, implying RB inactivation alone can
promote apoptosis in some settings (49, 50). Furthermore,
overexpression of RB in HeLa cells can suppress cell death
(51). The interaction between E1A and RB releases E2F
transcription factors; similarly, overexpression of E2F-1 over-
comes RB binding and induces apoptosis in a p53-dependent
manner (52). This finding suggests that one or more E2Fs
might mediate this aspect of E1A function. However, E2F-12/2
MEFs expressing E1A display no defects in apoptosis (L.
Yamasaki, A.V.S., and S.W.L., unpublished data), indicating
that E2F-1 is dispensable for this effect.
We have previously shown that p53 protein accumulates in
cells expressing E1A, which correlates with the involvement of
p53 in apoptosis (22, 23). Here we demonstrate that the same
E1A functions that promote apoptosis and chemosensitivity
also induce p53 (see also ref. 38). These regions are also
required for E1A’s transforming activities (13, 14), implying
that p53 accumulation, chemosensitivity, and oncogenic po-
tential arise from the same E1A functions. This suggests that
p53 accumulation is a cellular response to oncogenic ‘‘stress’’
rather than a direct effect of E1A on p53. Interestingly, extracts
FIG. 5. E1A and p53 accumulation. (A) p53 expression in popu-
lations of IMR90s or MEFs expressing the empty vector (V), full-
length E1A, DN, DCR2, or coexpressing DN and DCR2 was examined
by immunoblotting using polyclonal antibodies specific for human or
mouse p53, respectively. (B) p53 expression in wild-type, RB2/2,
p1072/2, or p1302/2 MEF populations expressing the indicated E1A
proteins. No increase in p53 was observed in RB2/2, p1072/2, or
p1302/2 MEFs without E1A, and E1A induced p53 in MEFs of all
three genotypes (data not shown.)
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from E1A-expressing cells possess a discrete factor that re-
produces some of the pro-apoptotic activities of E1A in
cell-free systems (27). The nature of this factor may shed light
on the links between p53, chemosensitivity, and cell-cycle
control.
The RB gene is mutated in many human cancers, and the RB
pathway is disrupted in the vast majority of cancer cells
(reviewed in ref. 18). Our results suggest a strategy to specif-
ically kill cancer cells with defective RB function. In normal
cells, at least two processes affected by E1A are necessary to
promote chemosensitivity—RB inactivation and apparently
disruption of some p300yCBP function. The RB-inactivating
function of E1A is dispensable for chemosensitivity in RB-
deficient cells, consequently such E1A mutants, or small
molecules that mimic their action, might synergize with stan-
dard chemotherapeutic agents to specifically induce apoptosis
in RB mutant tumor cells. Although p53 potentiates apoptosis
under the conditions used in this study, E1A can promote
chemosensitivity in p53-deficient cells (refs. 1 and 7, and
unpublished results). Consequently, this therapeutic approach
may not strictly depend on the presence of wild-type p53.
Experiments to test this strategy are underway.
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